IgA nephropathy (IgAN), also known as Berger disease, is currently the most common primary glomerular disease worldwide, its prevalence and incidence varying significantly from 30 to 40 cases per million people, largely based on ethnicity [1]. Natural history of IgAN is characterized by asymptomatic or pauci-symptomatic but progressive course, with up to 40% of patients reaching end-stage kidney disease
